HomeCompareFSGCY vs ABBV

FSGCY vs ABBV: Dividend Comparison 2026

FSGCY yields 4.63% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $74.4K in total portfolio value
10 years
FSGCY
FSGCY
● Live price
4.63%
Share price
$6.00
Annual div
$0.28
5Y div CAGR
1.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.9K
Annual income
$763.87
Full FSGCY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FSGCY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSGCYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSGCY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSGCY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSGCY
Annual income on $10K today (after 15% tax)
$393.75/yr
After 10yr DRIP, annual income (after tax)
$649.29/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,406.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSGCY + ABBV for your $10,000?

FSGCY: 50%ABBV: 50%
100% ABBV50/50100% FSGCY
Portfolio after 10yr
$65.1K
Annual income
$12,767.81/yr
Blended yield
19.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FSGCY
No analyst data
Altman Z
1.5
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSGCY buys
0
ABBV buys
0
No recent congressional trades found for FSGCY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSGCYABBV
Forward yield4.63%3.06%
Annual dividend / share$0.28$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR1.8%40.6%
Portfolio after 10y$27.9K$102.3K
Annual income after 10y$763.87$24,771.77
Total dividends collected$6.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FSGCY vs ABBV ($10,000, DRIP)

YearFSGCY PortfolioFSGCY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,172$471.57$11,550$430.00$378.00ABBV
2$12,455$501.22$13,472$627.96$1.0KABBV
3$13,858$531.63$15,906$926.08$2.0KABBV
4$15,391$562.79$19,071$1,382.55$3.7KABBV
5$17,063$594.67$23,302$2,095.81$6.2KABBV
6$18,885$627.23$29,150$3,237.93$10.3KABBV
7$20,867$660.46$37,536$5,121.41$16.7KABBV
8$23,022$694.32$50,079$8,338.38$27.1KABBV
9$25,363$728.80$69,753$14,065.80$44.4KABBV
10$27,902$763.87$102,337$24,771.77$74.4KABBV

FSGCY vs ABBV: Complete Analysis 2026

FSGCYStock

First Gen Corporation, through its subsidiaries, engages in the power generation business in Philippines. It operates through FGPC, FGP, FNPC, Prime Meridian, EDC and Subsidiaries, and FG Hydro segments. The FGPC segment operates Santa Rita, a 1,000 MW combined cycle, natural gas-fired power plant. The FGP segment operates San Lorenzo, a 500 MW combined cycle, natural gas-fired power plant. The FNPC segment owns and operates San Gabriel plant, a 420 MW natural gas-fired power plant. The Prime Meridian segment owns and operates Avion plant, a 97 MW open-cycle natural gas-fired power plant. The EDC and Subsidiaries segment holds service contracts with the Department of Energy to explore, develop, and utilize the resources in the relevant 10 geothermal contract areas. This segment owns and operates 588.4 MW Unified Leyte geothermal power plants; 172.5 MW Palinpinon geothermal power plants; 140.0 MW Bac-Man geothermal power plants; 123.0 MW Tongonan geothermal power plant; 106.0 MW Mindanao geothermal power plants; 49.4 MW Nasulo geothermal power plant; 150 MW Burgos Wind Energy project; 6.82 MW Burgos Solar Energy project; and 5.17 MW Solar Rooftop projects. The FG Hydro segment operates Pantabangan-Masiway, a 132 MW Hydroelectric Plant. It sells its electricity to Manila Electric Company, National Power Corporation, electric cooperatives, privately-owned distribution utilities, large industrial clients, and National Grid Corporation of the Philippines. As of December 31, 2021, the company had an installed capacity of 3,495 megawatts (MW). First Gen Corporation was incorporated in 1998 and is based in Pasig, the Philippines. First Gen Corporation is a subsidiary of First Philippine Holdings Corporation.

Full FSGCY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FSGCY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSGCY vs SCHDFSGCY vs JEPIFSGCY vs OFSGCY vs KOFSGCY vs MAINFSGCY vs JNJFSGCY vs MRKFSGCY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.